Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
TELA Bio, Inc.
Report date May 28, 2025 · Filed May 30, 2025
Section 16 reporting ended · disclosed 2021-06-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,470 |
Reported balance
After 2025-05-28 transaction · row 1
1 source rowRow 1 · 2025-05-28 · Grant · Acquired 7,950 · Balance 18,470 F1: These restricted stock units vest on the earlier of (a) May 28, 2026, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.39 · Expires 2035-05-28 | Direct | 11,700 |
Reported balance
After 2025-05-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-05-28 · Grant · Acquired 11,700 · Balance 11,700 F2: The option vests on the earlier of (a) May 28, 2026, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units vest on the earlier of (a) May 28, 2026, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date.
F2: The option vests on the earlier of (a) May 28, 2026, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 28, 2025 Filed May 30, 2025 20:17 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantStock Option (Right to Buy) · Derivative | 11,700 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0001062993-25-010576 · form4.xml · derivative · entry 2 Azarbarzin Kurt · CIK 0001792303 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,700 Underlying: Common Stock · 11,700 shares Expires 2035-05-28 F2 · derivative.exercise_date: The option vests on the earlier of (a) May 28, 2026, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| May 28, 2025 Filed May 30, 2025 20:17 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantCommon Stock | 7,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-010576 · form4.xml · nonDerivative · entry 1 Azarbarzin Kurt · CIK 0001792303 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,470 F1 · shares: These restricted stock units vest on the earlier of (a) May 28, 2026, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 21:00 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantStock Option (Right to Buy) · Derivative | 6,200 | $0.00 Strike: $5.71 | $0.00 |
DisclosureSEC source: 0001062993-24-012091 · form4.xml · derivative · entry 2 Azarbarzin Kurt · CIK 0001792303 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,200 Underlying: Common Stock · 6,200 shares Expires 2034-06-04 F2 · derivative.exercise_date: The option vests on the earlier of (a) June 4, 2025, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 21:00 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantCommon Stock | 4,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-012091 · form4.xml · nonDerivative · entry 1 Azarbarzin Kurt · CIK 0001792303 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,520 F1 · shares: These restricted stock units vest on the earlier of (a) June 4, 2025, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:37 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantStock Option (Right to Buy) · Derivative | 5,360 | $0.00 Strike: $10.34 | $0.00 |
DisclosureSEC source: 0001062993-23-012776 · form4.xml · derivative · entry 2 Azarbarzin Kurt · CIK 0001792303 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,360 Underlying: Common Stock · 5,360 shares Expires 2033-06-01 F2 · derivative.exercise_date: The option vests on the earlier of (a) June 1, 2024, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:37 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantCommon Stock | 3,135 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-012776 · form4.xml · nonDerivative · entry 1 Azarbarzin Kurt · CIK 0001792303 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,270 F1 · shares: These restricted stock units vest on the earlier of (a) June 1, 2024, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 20:04 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantStock Option (Right to Buy) · Derivative | 5,360 | $0.00 Strike: $6.84 | $0.00 |
DisclosureSEC source: 0001062993-22-014126 · form4.xml · derivative · entry 2 Azarbarzin Kurt · CIK 0001792303 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,360 Underlying: Common Stock · 5,360 shares Expires 2032-06-01 F2 · derivative.exercise_date: The option vests on the earlier of (a) June 1, 2023, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Peron's continued service through the applicable vesting date. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 20:04 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantCommon Stock | 3,135 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-014126 · form4.xml · nonDerivative · entry 1 Azarbarzin Kurt · CIK 0001792303 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,135 F1 · shares: These restricted stock units vest on the earlier of (a) June 1, 2023, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Peron's continued service through the applicable vesting date. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 20:55 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantStock Option (Right to Buy) · Derivative | 10,825 | $0.00 Strike: $13.16 | $0.00 |
DisclosureSEC source: 0001192482-21-000490 · edgar.xml · derivative · entry 1 Azarbarzin Kurt · CIK 0001792303 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,825 Underlying: Common Stock · 10,825 shares Expires 2031-06-02 F1 · derivative.exercise_date: The option vests on the earlier of (a) June 2, 2022, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:37 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantStock Option (Right to Buy) · Derivative | 8,806 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001192482-20-000449 · edgar.xml · derivative · entry 1 Azarbarzin Kurt · CIK 0001792303 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,806 Underlying: Common Stock · 8,806 shares Expires 2030-06-04 F1 · derivative.exercise_date: The option vests on the earlier of (a) the first anniversary of June 4, 2020, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's 2019 Equity Incentive Plan), subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 01:52 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionWarrant (right to buy) · Derivative | 1,665 | $0.00 Strike: $28.65 | $0.00 |
DisclosureSEC source: 0001192482-19-000424 · edgar.xml · derivative · entry 14 Azarbarzin Kurt · CIK 0001792303 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By HighCape Partners, L.P. Disclosed balance after: 1,665 Underlying: Common Stock · 67 shares Expires 2027-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · kind: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 01:52 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionWarrant (right to buy) · Derivative | 1,665 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001192482-19-000424 · edgar.xml · derivative · entry 13 Azarbarzin Kurt · CIK 0001792303 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By HighCape Partners, L.P. Disclosed balance after: 0 Underlying: Series B Preferred Stock · 1,665 shares Expires 2027-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · kind: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 01:52 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionWarrant (right to buy) · Derivative | 123,653 | $0.00 Strike: $28.65 | $0.00 |
DisclosureSEC source: 0001192482-19-000424 · edgar.xml · derivative · entry 12 Azarbarzin Kurt · CIK 0001792303 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By HighCape Partners QP, L.P. Disclosed balance after: 123,653 Underlying: Common Stock · 5,008 shares Expires 2027-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · kind: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 01:52 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionWarrant (right to buy) · Derivative | 123,653 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001192482-19-000424 · edgar.xml · derivative · entry 11 Azarbarzin Kurt · CIK 0001792303 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By HighCape Partners QP, L.P. Disclosed balance after: 0 Underlying: Series B Preferred Stock · 123,653 shares Expires 2027-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · kind: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 01:52 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionSeries B Preferred Stock · Derivative | 72,417 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-19-000424 · edgar.xml · derivative · entry 10 Azarbarzin Kurt · CIK 0001792303 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By HighCape Partners, L.P. Disclosed balance after: 0 Underlying: Common Stock · 2,931 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F4 · derivative.exercise_date: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F4 · derivative.expiration_date: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F5 · derivative.underlying_shares: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 01:52 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionSeries B Preferred Stock · Derivative | 5,377,928 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-19-000424 · edgar.xml · derivative · entry 9 Azarbarzin Kurt · CIK 0001792303 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By HighCape Partners QP, L.P. Disclosed balance after: 0 Underlying: Common Stock · 217,816 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F4 · derivative.exercise_date: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F4 · derivative.expiration_date: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F5 · derivative.underlying_shares: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 01:52 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionSeries A Preferred Stock · Derivative | 6,643 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-19-000424 · edgar.xml · derivative · entry 8 Azarbarzin Kurt · CIK 0001792303 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By HighCape Partners, L.P. Disclosed balance after: 0 Underlying: Common Stock · 269 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F3 · derivative.exercise_date: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F3 · derivative.expiration_date: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F5 · derivative.underlying_shares: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 01:52 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionSeries A Preferred Stock · Derivative | 493,357 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-19-000424 · edgar.xml · derivative · entry 7 Azarbarzin Kurt · CIK 0001792303 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By HighCape Partners QP, L.P. Disclosed balance after: 0 Underlying: Common Stock · 19,982 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F3 · derivative.exercise_date: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F3 · derivative.expiration_date: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F5 · derivative.underlying_shares: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 01:52 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionCommon Stock | 217,816 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-19-000424 · edgar.xml · nonDerivative · entry 6 Azarbarzin Kurt · CIK 0001792303 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By HighCape Partners QP, L.P. Disclosed balance after: 498,606 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 01:52 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionCommon Stock | 19,982 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-19-000424 · edgar.xml · nonDerivative · entry 5 Azarbarzin Kurt · CIK 0001792303 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By HighCape Partners QP, L.P. Disclosed balance after: 280,790 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 01:52 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionCommon Stock | 2,931 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-19-000424 · edgar.xml · nonDerivative · entry 4 Azarbarzin Kurt · CIK 0001792303 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By HighCape Partners, L.P. Disclosed balance after: 15,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 01:52 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionCommon Stock | 269 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-19-000424 · edgar.xml · nonDerivative · entry 3 Azarbarzin Kurt · CIK 0001792303 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By HighCape Partners, L.P. Disclosed balance after: 12,944 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. Read SEC document |
| November 08, 2019 Filed Nov 14, 2019 01:52 UTC | TELA Bio, Inc. TELA · Entity 7381 | PurchaseCommon Stock | 75,901 | $13.00 | $986,713.00 |
DisclosureSEC source: 0001192482-19-000424 · edgar.xml · nonDerivative · entry 2 Azarbarzin Kurt · CIK 0001792303 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By HighCape Partners QP, L.P. Disclosed balance after: 260,808 F2 · balance_after: Reflects 183,907 shares of common stock received by the reporting person as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a). Read SEC document |
| November 08, 2019 Filed Nov 14, 2019 01:52 UTC | TELA Bio, Inc. TELA · Entity 7381 | PurchaseCommon Stock | 10,220 | $13.00 | $132,860.00 |
DisclosureSEC source: 0001192482-19-000424 · edgar.xml · nonDerivative · entry 1 Azarbarzin Kurt · CIK 0001792303 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By HighCape Partners, L.P. Disclosed balance after: 12,675 F1 · balance_after: Reflects 2,455 shares of common stock received by the reporting person as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.